Skip to main content

Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

2,065 trials, most industry funding first

  1. Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

    Active, not recruiting · Phase 1, Phase 2 · Hemophilia B

    NCT01687608 · Takeda Pharmaceuticals U.S.A., Inc. · 1 U.S. investigator

    $204research payments

  2. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    Recruiting · Phase 3 · Depressive Disorder, Major

    NCT07412756 · Eli Lilly and Company · 3 U.S. investigators

    $188research payments

  3. A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

    Completed · Multiple Myeloma

    NCT03106324 · Celgene Corporation · 0 U.S. investigators

    $175research payments

  4. A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

    Active, not recruiting · Phase 3 · Breast Cancer

    NCT02246621 · Eli Lilly and Company · 1 U.S. investigator

    $168research payments

  5. A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

    Completed · Phase 1 · Healthy Volunteers

    NCT06715683 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $151research payments

  6. A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

    Completed · Phase 3 · Obesity

    NCT05931380 · Eli Lilly and Company · 3 U.S. investigators

    $132research payments

  7. A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

    Completed · Phase 2 · Alzheimer Disease

    NCT04640077 · Eli Lilly and Company · 1 U.S. investigator

    $126research payments

  8. A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

    Active, not recruiting · Phase 1 · Advanced Solid Tumors Cancer

    NCT02099058 · AbbVie Inc. · 2 U.S. investigators

    $120research payments

  9. A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

    Terminated · Phase 1 · Hepatic Insufficiency

    NCT05209295 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $111research payments

  10. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    Recruiting · Phase 3 · Obesity

    NCT07321886 · Eli Lilly and Company · 1 U.S. investigator

    $95research payments

  11. A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

    Completed · Phase 2 · Pseudoxanthoma Elasticum

    NCT05569252 · Daiichi Sankyo Inc. · 1 U.S. investigator

    $72research payments

  12. Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

    Completed · Phase 2 · Post-Operative Atrial Fibrillation

    NCT03779841 · AbbVie Inc. · 0 U.S. investigators

    $67research payments

  13. A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

    Completed · Phase 3 · Atopic Dermatitis

    NCT03952559 · Eli Lilly and Company · 2 U.S. investigators

    $53research payments

  14. A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

    Terminated · Phase 2 · Rheumatoid Arthritis

    NCT06859294 · Eli Lilly and Company · 1 U.S. investigator

    $12research payments

  15. A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

    Completed · Phase 3 · Type 2 Diabetes Mellitus

    NCT03730662 · Eli Lilly and Company · 1 U.S. investigator

    $3research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.

About this page

Industry-funded clinical trials test new drugs and devices in patients. This list shows trials for which drug and device companies reported research payments to CMS, linked to their ClinicalTrials.gov records. For each trial, you can see the sponsor, phase and status, the U.S. physicians named as principal investigators, and how much the company paid for the research.

How to search industry-funded clinical trials

First, search by drug, condition or company. Then open a trial to see its investigators and study sites. You can also start from a doctor’s page, which lists the trials that doctor helps lead. In addition, drug and specialty pages link to the trials in their field.

What the payments mean

Research payments usually go to hospitals and universities to run the study. In other words, the money pays for the research, not the investigator personally. Companies report these payments under the federal Sunshine Act, and CMS publishes them in Open Payments (opens in a new tab). However, a payment record alone does not show how a study was run or what it found.

Joining a clinical trial

If you want to join a trial, start with the official record on ClinicalTrials.gov (opens in a new tab). It lists who can take part, where and how to contact the study team. Also talk to your doctor first, because a trial may not be right for you.

Related: Medicare drugs, drug company payments to doctors, specialties.

Questions about industry-funded clinical trials

Are industry-funded clinical trials safe? Every trial in the U.S. needs approval from an ethics board, and drug trials also follow FDA rules. However, every trial carries some risk. So read the consent form carefully and ask questions.

Who is a principal investigator? The principal investigator is the doctor who leads the study at a site. Their page here shows their other trials and the payments companies reported for that research.

Why are some trials missing? We list trials with industry research payments in Open Payments. As a result, trials funded only by the government or universities do not appear.